Gyre Therapeutics, Inc. GYRE Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Gyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The official record: Gyre Therapeutics, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Gyre Therapeutics, Inc.'s financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Gyre Therapeutics, Inc.'s financing cash flow?
- Gyre Therapeutics, Inc. (GYRE) reported financing cash flow of $21K in Q1 2026.
- How has Gyre Therapeutics, Inc.'s financing cash flow changed year-over-year?
- Gyre Therapeutics, Inc.'s financing cash flow decreased by 98.4% year-over-year, from $1.34M to $21K.
- What is the long-term trend for Gyre Therapeutics, Inc.'s financing cash flow?
- Over 2 years (2023 to 2025), Gyre Therapeutics, Inc.'s financing cash flow has grown at a 212.3% compound annual growth rate (CAGR), from $2.5M to $24.38M.
- What does financing cash flow mean?
- Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.